Effects of the continuous subcutaneous infusion of foslevodopa-foscarbidopa on swallowing in patients with Parkinson’s disease

Background: Dysphagia is a potentially fatal symptom of Parkinson’s disease (PD) and is characterized by frequent silent aspiration, a known risk factor for aspiration pneumonia. A previous study has reported that the dopamine agonist rotigotine (levodopa equivalent dose of 60 mg/day) delivered via...

Full beskrivning

Bibliografiska uppgifter

Huvudupphov:	Makito Hirano, Makoto Samukawa, Chiharu Isono, Rino Inada, Yuta Fukumoto, Keisuke Yoshikawa, Hitoshi Namura, Hanami Sakata, Takahiro Hisatomi, Toru Michiura, Hiroto Nakamura, Akira Morita, Genki Hoshino, Kensuke Yamana, Atsushi Terayama, Yuji Higashimoto, Yoshiyuki Mitsui, Yoshitaka Nagai
Materialtyp:	Artigo
Språk:	Inglês
Utgiven:	Elsevier 2025-01-01
Serie:	Clinical Parkinsonism & Related Disorders
Ämnen:	Dysphagia Parkinson’s disease DOSS Deglutition CSCI of foslevodopa/foscarbidopa
Länkar:	http://www.sciencedirect.com/science/article/pii/S2590112525000829
Taggar:	Lägg till en tagg Inga taggar, Lägg till första taggen!